Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc.（ALLO）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · ALLO · 截至 2025年3月31日
股东结构概览
173
机构持有人数
▼ 2 vs Q4
$301.80M
机构持仓总市值
▼ $100.06M vs Q4
243.87M
总流通股
freeFloat 66.53%
197.13M
13F 申报持股数
▲ 8.47M vs Q4
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
ALLO 最大股东 · 机构持仓
Q1 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
PFIZER INC biological products, (no diagnostic substances) | 22.03M | 10.23% | 10.23% | $32.17B | May 13, 2025 | — held |
TPG GP A, LLC biological products, (no diagnostic substances) | 18.72M | 8.69% | 8.69% | $27.33B | May 15, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 17.93M | 8.33% | 8.33% | $26.18B | May 2, 2025 | ▼ 129.7K |
CAPITAL WORLD INVESTORS biological products, (no diagnostic substances) | 12.27M | 5.70% | 5.70% | $17.91B | May 12, 2025 | ▲ 5.37M |
LYNX1 CAPITAL MANAGEMENT LP biological products, (no diagnostic substances) | 11.06M | 5.13% | 5.13% | $16.14B | May 15, 2025 | ▲ 182.3K |
DARWIN GLOBAL MANAGEMENT, LTD. biological products, (no diagnostic substances) | 10.45M | 4.85% | 4.85% | $16.20B | May 15, 2025 | NEW |
CITADEL ADVISORS LLC biological products, (no diagnostic substances) | 10.20M | 4.74% | 4.74% | $14.90B | May 15, 2025 | ▲ 4.85M |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 8.07M | 3.75% | 3.75% | $11.78B | May 9, 2025 | ▲ 66.9K |
FMR LLC biological products, (no diagnostic substances) | 7.39M | 3.43% | 3.43% | $10.80B | May 12, 2025 | ▼ 16.38M |
GOLDMAN SACHS GROUP INC biological products, (no diagnostic substances) | 5.85M | 2.72% | 2.72% | $8.55B | Jun 27, 2025 | ▲ 3.75M |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q1 2025 对比上季度
Q1 2025
24
增持
+23.47M 股3
新建仓
首次建仓16
减持
−23.39M 股0
清仓
完全退出净股数变化（前50家）
+79.3K
+23.47M / −23.39M
净新增持仓人
+11
新建 3 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
ALLO 内幕交易记录
数据来源：SEC Form 4
近期内部人员以卖出为主。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
0
买入笔数
1
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Yoshiyama Annie SVP, Finance | Apr 21, 2026 | Sale | 9,586 | $2.31 | $22.1K | 124.5K | Form 4 ↗ |
Beneski Benjamin Machinas SVP, Chief Technical Officer | Mar 31, 2026 | Sale | 2,867 | $2.50 | $7.2K | 195.3K | Form 4 ↗ |
Beneski Benjamin Machinas SVP, Chief Technical Officer | Mar 16, 2026 | Sale | 4,835 | $2.47 | $11.9K | 198.2K | Form 4 ↗ |
Chang David D President and CEO | Mar 16, 2026 | Sale | 47,763 | $2.47 | $118.0K | 5.15M | Form 4 ↗ |
Beneski Benjamin Machinas SVP, Chief Technical Officer | Mar 2, 2026 | Sale | 7,132 | $2.60 | $18.5K | 203.0K | Form 4 ↗ |
Beneski Benjamin Machinas SVP, Chief Technical Officer | Feb 2, 2026 | Award | 373,757 | $1.87 | $698.9K | 373.8K | Form 4 ↗ |
Beneski Benjamin Machinas SVP, Chief Technical Officer | Feb 2, 2026 | Sale | 7,549 | $1.73 | $13.1K | 210.2K | Form 4 ↗ |
Chang David D President and CEO | Feb 2, 2026 | Sale | 95,269 | $1.80 | $171.5K | 5.19M | Form 4 ↗ |
Chang David D President and CEO | Feb 2, 2026 | Award | 1,387,931 | $1.87 | $2.60M | 1.39M | Form 4 ↗ |
Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Feb 2, 2026 | Sale | 24,001 | $1.76 | $42.2K | 1.25M | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Allogene Therapeutics, Inc.（ALLO）主要由机构投资者持有，机构持股比例约为 80.8%。公司内部人员持股约 33.47%，散户及公众持股约占剩余的 0.00%。
Allogene Therapeutics, Inc. 最大机构股东为 PFIZER INC，截至 March 31, 2025 持有约 22.03 million 股，占总流通股的 10.23%。
目前共有 173 家机构持有 ALLO 股票，合计持仓市值约 $301,796,493，数据来源为最新 SEC 13F 申报。
常见问题
ALLO ownershipAllogene Therapeutics, Inc.（ALLO）主要由机构投资者持有，机构持股约 80.8%。最大股东为 PFIZER INC，持股比例 10.23%。内部人员持股约 33.47%。数据来源 SEC Form 13F，截至 March 31, 2025。